Wells Fargo Downgrades Halozyme Therapeutics to Equal-Weight, Raises Price Target to $62
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo has downgraded Halozyme Therapeutics from Overweight to Equal-Weight, while raising the price target from $58 to $62.
October 07, 2024 | 4:31 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Wells Fargo downgraded Halozyme Therapeutics from Overweight to Equal-Weight, indicating a more neutral stance on the stock. However, the price target was raised to $62, suggesting some positive outlook.
The downgrade from Overweight to Equal-Weight suggests a less bullish view, which could lead to a neutral short-term impact on the stock price. However, the raised price target to $62 indicates some positive expectations, balancing the overall impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100